- Home
- ABSI vs TSHA Comparison
ABSI vs TSHA Comparison
Compare ABSI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- TSHA
- Stock Information
- Founded
- ABSI 2011
- TSHA 2019
- Country
- ABSI United States
- TSHA United States
- Employees
- ABSI N/A
- TSHA N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- TSHA Health Care
- Exchange
- ABSI Nasdaq
- TSHA Nasdaq
- Market Cap
- ABSI 353.8M
- TSHA 356.7M
- IPO Year
- ABSI 2021
- TSHA 2020
- Fundamental
- Price
- ABSI $3.05
- TSHA $1.66
- Analyst Decision
- ABSI Strong Buy
- TSHA Strong Buy
- Analyst Count
- ABSI 6
- TSHA 8
- Target Price
- ABSI $7.83
- TSHA $6.63
- AVG Volume (30 Days)
- ABSI 4.2M
- TSHA 1.7M
- Earning Date
- ABSI 03-18-2025
- TSHA 05-13-2025
- Dividend Yield
- ABSI N/A
- TSHA N/A
- EPS Growth
- ABSI N/A
- TSHA N/A
- EPS
- ABSI N/A
- TSHA N/A
- Revenue
- ABSI $4,534,000.00
- TSHA $8,333,000.00
- Revenue This Year
- ABSI $257.06
- TSHA N/A
- Revenue Next Year
- ABSI $112.29
- TSHA N/A
- P/E Ratio
- ABSI N/A
- TSHA N/A
- Revenue Growth
- ABSI N/A
- TSHA N/A
- 52 Week Low
- ABSI $2.45
- TSHA $1.19
- 52 Week High
- ABSI $6.72
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- ABSI 41.19
- TSHA 43.73
- Support Level
- ABSI $2.81
- TSHA $1.59
- Resistance Level
- ABSI $3.15
- TSHA $1.87
- Average True Range (ATR)
- ABSI 0.21
- TSHA 0.10
- MACD
- ABSI -0.01
- TSHA -0.01
- Stochastic Oscillator
- ABSI 48.74
- TSHA 8.93
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.